Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients

Wen, Shirong; Liu, Guojun; Feng, Rennan; Gong, Fei; Zhong, Hua; Duan, Shanshan; Bi, Sheng

doi:10.1016/j.jneuroim.2011.12.004

Cited by 70 publications

(43 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the median CSF OPN level of MS patients was in accordance with data published by others [31,33]. However, CSF OPN level in patients with neuroinflammatory disease, e.g.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

et al. 2016

View full text Add to dashboard Cite

Central nervous system lymphoma (CNSL) is diagnostically challenging. The identification of reliable and easy to measure biomarkers is desirable to facilitate diagnosis. Here, we evaluated the value of cerebrospinal fluid (CSF) osteopontin (OPN) as a diagnostic biomarker for CNSL. OPN concentrations in CSF from 37 patients with CNSL (29 with primary CNSL and 8 with secondary CNS involvement of systemic lymphoma) and 36 controls [6 patients with inflammatory CNS disease other than multiple sclerosis (MS), 8 with MS, 9 with glioblastoma (GBM) and 13 healthy controls] were determined using an enzyme-linked immunosorbent assay. Non-parametric tests and receiver operating characteristic (ROC) curves were performed for determination of diagnostic accuracy. Median CSF OPN level in all CNSL patients was 620 ng/mL and higher than in patients with inflammatory CNS disease (356 ng/mL); P < .05, MS (163 ng/mL); P < .01, GBM (41 ng/mL); P < .01, or healthy controls (319 ng/mL); P < .01. The area under the ROC curve was 0.865 [95 % confidence interval (CI) 0.745-0.985] for differentiating CNSL and patients with inflammatory CNS disease; 0.956 (95 % CI 0.898-1.000) for CNSL and MS patients; 0.988 (95 % CI 0.964-1.000) for CNSL and GBM patients, and 0.915 (95 % CI 0.834-0.996) for CNSL patients and healthy controls. In multivariate analysis, high CSF OPN level was associated with shorter progression-free (HR 1.61, 95 % CI 1.13-2.31; P = .009) and overall survival (HR 1.52, 95 % CI 1.04-2.21; P = .029). CSF OPN is a potential biomarker in CNSL.

show abstract

“…In our study, the median CSF OPN level of MS patients was in accordance with data published by others [31,33]. However, CSF OPN level in patients with neuroinflammatory disease, e.g.…”

Section: Discussionsupporting

confidence: 92%

“…Numerous studies reported increased CSF OPN levels in patients with MS and other neuroinflammatory and neurodegenerative diseases [30][31][32][33]. In our study, the median CSF OPN level of MS patients was in accordance with data published by others [31,33].…”

Section: Discussionsupporting

confidence: 92%

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For its action in the regulation of immune system, OPN has been recognized to have a role in the development/progression of several autoimmune diseases, such as multiple sclerosis (16,17,18,19) rheumatoid arthritis (20,21), psoriasis (22) and Graves' disease (23).…”

Section: Introductionmentioning

confidence: 99%

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

Barchetta¹,

Alessandri

Bertoccini³

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Osteopontin (OPN) is a sialoprotein implicated in different immunity and metabolic pathways. Capable of activating dendritic cells and inducing Th1-Th17-mediated tissue damage, OPN plays a significant role in the development/progression of several autoimmune diseases; interestingly, it was also shown that OPN participates in the acute pancreatic islets response to experimentally induced diabetes in non-obese diabetic (NOD) mice. Furthermore, OPN promotes adipose tissue dysfunction, systemic inflammation and insulin resistance. Our aims of this study were to evaluate circulating OPN levels in adult patients with type 1 diabetes mellitus (T1DM) compared to non-diabetic control participants and to unravel clinical and biochemical correlates of OPN concentration. Design: Case-control study. Methods: We enrolled 54 consecutive T1DM patients referred to our diabetes outpatient clinic at Sapienza University of Rome and 52 healthy sex and age-comparable controls. The study population underwent clinical evaluation, blood sampling for biochemistry and complete screening for diabetes complications. Serum OPN levels were measured by MILLIPLEX Multiplex Assays Luminex. Results: T1DM patients had significantly higher serum OPN levels than controls (17.2G12.9 vs 10.5G11.6 mg/ml, PZ0.009). OPN levels correlated with T1DM, higher blood pressure, BMI, creatinine, g-GT, ALP and lower HDL; the association between high OPN levels and T1DM was independent from all confounders. No correlation was shown between OPN and HbA1c, C-peptide, insulin requirement, co-medications and diabetes duration. Conclusions: This study demonstrates for the first time in a case-control study that adults with T1DM have increased serum OPN levels, and that higher OPN concentrations are associated with an unfavorable metabolic profile in these patients.

show abstract

“…Studies have shown that inflammatory gluten-reactive T cells recognizing gluten selectively in the context of the HLA region (alleles coding the heterodimers HLA-DQ2 or HLA-DQ8) are presented only in the small intestinal mucosa of individuals with CD (Abadie et al, 2011). Pro-inflammatory cytokines are also known to play an important role in disease progression and tissue damage in autoimmune diseases such as multiple sclerosis (Wen et al, 2012), rheumatoid arthritis (Kishimoto, 2006), and systemic lupus erythematosus (Dienz and Rincon, 2009). …”

Section: Introductionmentioning

confidence: 99%

Tumor necrosis factor-α and interleukin-6 gene polymorphism association with susceptibility to celiac disease in Italian patients

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. The aim of this research was to study polymorphisms in the genes encoding cytokines interleukin-6 (IL-6) and tumor necrosis factoralpha (TNF-α) in patients with celiac disease (CD) antigens DQ2 (DQ2-positive) or DQ8 (DQ8-positive). We compared the results with healthy controls to determine whether any of the polymorphisms have a role in susceptibility to CD. 16343-16352 (2015) included in the study. Analysis of single nucleotide polymorphisms (SNPs) was carried out using the polymerase chain reaction-restriction fragment length polymorphism method. Significant differences for the TNF-α (-308 G>A) polymorphism were observed when we compared the flowing groups: DQ2-positive with controls [odds ratio (OR) = 0.45, P = 0.0002]; DQ8-positive with controls (OR = 3.55, P < 0.0001); and DQ2-positive with DQ8-positive (OR = 0.12, P < 0.0001). We did not observe a statistically significant association between IL-6 (-174 G>C) polymorphism and CD (P > 0.05). Our results suggest that TNF-α (-308 G>A) polymorphism may play a role in susceptibility to CD in Italian patients.

show abstract

Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients

Cited by 70 publications

References 17 publications

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

Tumor necrosis factor-α and interleukin-6 gene polymorphism association with susceptibility to celiac disease in Italian patients

Contact Info

Product

Resources

About